search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


29 resulaten gevonden voor Koningin Wilhelmina Fonds (KWF) in trials

A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation
- TRIAL ID
NTR6751
- ACRONYMHOVON 134 MF
Cancer@Work; a web-based intervention to improve the return-to-work of cancer survivors
- TRIAL ID
NTR5190
- ACRONYMCancer@Work
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
- TRIAL ID
NTR2477
- ACRONYMHOVON 103 AML Tosedostat
Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup study.
- TRIAL ID
NTR2427
- ACRONYMHOVON 105 PCNSL
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
- TRIAL ID
NTR2294
- ACRONYMHOVON 103 AML Lenalidomide
Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS =>1.5).
- TRIAL ID
NTR2187
- ACRONYMHOVON 102 AML
Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77).
- TRIAL ID
NTR2086
- ACRONYMHOVON 77 NHL
Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults.
- TRIAL ID
NTR2004
- ACRONYMHOVON 100 ALL
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation.
- TRIAL ID
NTR1757
- ACRONYMHOVON 80 NHL
Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS >= 1.5)
- TRIAL ID
NTR1446
- ACRONYMHOVON 92 AML
RNA-DC vaccination in multiple myeloma.
- TRIAL ID
NTR1086
- ACRONYMN/A
A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.
- TRIAL ID
NTR904
- ACRONYMHOVON 81 AML
Anti-CD20 therapy for the treatment of chronic graft versus host disease.
- TRIAL ID
NTR709
- ACRONYMR'mabcGVHD
Dutch Belgian randomised lung cancer screening trial (NELSON).
- TRIAL ID
NTR636
- ACRONYMNELSON
Simply Capecitabine in rectal cancer after irradiation plus TME.
- TRIAL ID
NTR552
- ACRONYMSCRIPT
PORTEC-2: Postoperative Radiation Therapy for Endometrial Carcinoma – a multicenter randomised phase III trial comparing external beam radiation and vaginal brachytherapy.
- TRIAL ID
NTR332
- ACRONYMPORTEC-2
Postoperative Accelerated RadioTherapy versus conventional radiotherapy in squamous cell head and neck cancer (POPART). A phase III randomised study.
- TRIAL ID
NTR310
- ACRONYMPOPART, CKTO 2003-11
Microarray Analysis in breast cancer to Tailor Adjuvant Drugs Or Regimens, a randomized phase III study.
- TRIAL ID
NTR286
- ACRONYMMATADOR, BOOG 2005-02, CKTO 2004-04
The effect of comprehensive counseling by a nurse specialist on depressive symptoms and quality of life: A prospective randomized study in patients with head and neck cancer.
- TRIAL ID
NTR257
- ACRONYMNUCAI
Intensified CHOP of 12-weeks duration plus G-CSF as compared with standard CHOP of 24-weeks duration for patients with intermediate-prognosis Non Hodgkin’s Lymphoma.
- TRIAL ID
NTR239
- ACRONYMHOVON 26 NHL
A randomized phase III study on the effect of Thalidomide combined with Adriamycin, Dexamethasone (AD) and High Dose Melphalan in patients with multiple myeloma.
- TRIAL ID
NTR238
- ACRONYMHOVON 50 MM / GMMG-HD3
A randomized phase III study of i.v. zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma. A phase III study.
- TRIAL ID
NTR233
- ACRONYMHOVON 50 MM
Randomized phase III study in elderly patients with a multiple myeloma on the value of Thalidomide added to Melphalan plus Prednisone.
- TRIAL ID
NTR232
- ACRONYMHOVON 49 MM
Randomized induction and post induction therapy in adult patients (<= 60 yrs of age) with acute myelocytic leukemia (AML) or refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score >= 1.5.
- TRIAL ID
NTR230
- ACRONYMHOVON/SAKK 42 AML
Early intensification by (un)related allogeneic or autologous stem cell transplantation in adult acute lymphoblastic leukemia. A phase II study.
- TRIAL ID
NTR228
- ACRONYMHOVON 37 ALL
A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenance in patients with multiple myeloma.
- TRIAL ID
NTR213
- ACRONYMHOVON 65 MM / GMMG-HD4
Randomized induction and post induction therapy in older patients (>= 61 yrs of age) with acute myelocytic leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t).
- TRIAL ID
NTR212
- ACRONYMHOVON 43 AML / SAKK 30/01
A randomized phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (MabThera) during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapsed or progressive B-cell non-Hodgkin’s lymphoma.
- TRIAL ID
NTR188
- ACRONYMHOVON 44 NHL
European Randomized Study of Screening for Prostate Cancer.
- TRIAL ID
NTR156
- ACRONYMERSPC